INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,530,000 shares, an increase of 6.3% from the March 15th total of 1,440,000 shares. Currently, 13.0% of the shares of the stock are sold short. Based on an average trading volume of 86,500 shares, the short-interest ratio is presently 17.7 days.

INmune Bio Trading Down 7.9 %

Shares of NASDAQ:INMB opened at $8.43 on Thursday. The company has a 50 day moving average of $11.74 and a 200-day moving average of $10.26. The firm has a market cap of $151.96 million, a P/E ratio of -5.05 and a beta of 1.99. INmune Bio has a twelve month low of $6.50 and a twelve month high of $14.74.

Institutional Trading of INmune Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC acquired a new stake in INmune Bio during the third quarter valued at approximately $25,000. Bank of America Corp DE lifted its position in shares of INmune Bio by 152.1% in the 1st quarter. Bank of America Corp DE now owns 4,717 shares of the company’s stock valued at $30,000 after acquiring an additional 2,846 shares in the last quarter. Advisor Group Holdings Inc. lifted its position in shares of INmune Bio by 52.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 9,250 shares of the company’s stock valued at $59,000 after acquiring an additional 3,200 shares in the last quarter. LPL Financial LLC purchased a new stake in shares of INmune Bio in the 3rd quarter valued at approximately $68,000. Finally, Osaic Holdings Inc. lifted its position in shares of INmune Bio by 41.1% in the 2nd quarter. Osaic Holdings Inc. now owns 11,200 shares of the company’s stock valued at $102,000 after acquiring an additional 3,265 shares in the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression.